黃耆與人參皂苷萃取物複方對人體血糖和血脂調節的影響

研究證實黃耆或人參的皂苷萃取物，對於動物的血糖或血脂調節具有功效。由於目前沒有關於同時添加黃耆皂苷與人參皂苷對於人體血糖和血脂調節的相關研究。本研究目的為探討黃耆與人參皂苷萃取物複方(ANS)對於血糖偏高且高血脂者的影響，採隨機雙盲交叉人體試驗。受試者為20歲以上之成年人，空腹血糖介於100~125mg/dl且HbA1c 5.8%~6.4%和膽固醇介於200~249 mg/dl。受試者每天補充5顆ANS膠囊或安慰劑(早上餐前2顆；晚上餐前3顆)連續六週，每三週檢測空腹血糖、葡萄糖耐受試驗(OGTT)、血脂、小而低密度脂蛋白膽固醇 (sdLDL-C)、高密度脂蛋白膽固醇 (HDL-C)、脂聯素(adiponectin)、瘦體素(Leptin)、糖化血色素、單磷酸腺苷活化蛋白激酶(adenosine monophosphate activated protease kinase, AMPK)等項目。另外分析肝、腎功能，作為觀察補充黃耆與人參皂苷萃取物複方或安慰劑是否會對人體造成其他影響。完成試驗者為9位，結果發現補充黃耆與人參皂苷萃取物複方六週後，空腹血糖和葡萄糖耐受試驗OGTT的AUC分別顯著低於安慰劑組10.1%及12.69% (p<0.05)。三酸甘油酯和sdLDL-C分別顯著低於安慰劑組31.06%及19.96% (p<0.05)。且HDL-C、脂聯素與AMPK分別顯著高於安慰劑組11.78%、22.07%及12.72% (p<0.05)。黃耆與人參皂苷萃取物複方對於人體肝腎功能及各項安全性指標，試驗前後並無顯著差異。試驗結果表示黃耆與人參皂苷萃取物複方可幫助血糖偏高且高血脂者調節血糖與血脂，且無副作用。

Astragalus membranaceus and Panax notoginseng extracts contains saponins. Many studies in animals have confirmed that saponins of astragalus and ginseng extracts have potential effects on the regulation of blood glucose or blood lipids. There has been no research among humans on the simultaneous use of astragalus and ginseng extracts. The purpose of this study was to investigate the effect of Astragalus membranaceus and Panax notoginseng extracts compound contains saponins (ANS) on the regulation of hyperglycemia and dyslipidemia. This was a randomized, double-blind crossover trial among people aged above 20 years, with fasting blood glucose level 100~125mg/dl, HbA1c 5.8%~6.4%, and cholesterol 200~249 mg/dl. After confirmimg the subjects’ eligibility, they were acked to take 5 ANS or placebos capsules (2 capsules before breakfast and 3 capsules before dinner) daily for six weeks. The changes in blood glucose and lipids were measured every three weeks. Fasting blood glucose, OGTT, blood lipids, Small dense low-density lipoprotein-cholesterol (sdLDL-C), High density lipoprotein cholesterol (HDL-C), adiponectin, leptin, glycosylated hemoglobin (HbA1c), adenosine monophosphate activated protease kinase (AMPK) were measured. In addition, liver and kidney function were analyzed, to check for any adverse effects associated with ANS or placebo. In all, 9 people completed the study. The results showed the fasting blood glucose and AUC after six weeks of oral supplementation ANS were significantly lower than the placebo group by 10.1% and 12.69% (p<0.05). TG and sdLDL-C significantly lower than the placebo group by 31.06 % and 19.96% (p<0.05). HDL-C, Adiponectin, and AMPK significantly increased than the placebo group by 11.78%, 22.07% and 12.72% (p<0.05). The results show that oral supplementation ANS can reduce hyperglycemia and dyslipidemia, and no adverse events were reported.